Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Abbvie Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the import, export, supply, and evaluation of therapeutic goods in Australia, addressing the need for a comprehensive legislative framework to ensure the safety, efficacy, and quality of these goods. This Act was established by the Commonwealth of Australia and its objective is to protect public health by ensuring that therapeutic goods available in Australia meet appropriate standards. In a specific instance, a delegate of the Secretary of the Department of Health granted consent under sections 14 and 14A of the Act to Abbvie Pty Ltd for the importation and supply of certain therapeutic goods, namely VIEKIRA PAK-RBV, which were not fully compliant with the Therapeutic Goods Order No. 69 regarding the labelling of medicines. This consent, effective from 26 November 2015 until 31 July 2016, was subject to certain conditions aimed at mitigating any potential risks to public health while still facilitating the availability of these therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia’s Department of Health, applies to the regulation of therapeutic goods, including medicines, medical devices, and blood and tissues. The Act governs the import, export, manufacture, and supply of these goods, ensuring they meet safety, quality, and efficacy standards. The Act applies to individuals, healthcare professionals, manufacturers, importers, and suppliers of therapeutic goods within Australia. It has a national jurisdictional reach, with the TGA operating under federal authority to enforce compliance across all states and territories. Specific exclusions or exemptions within the Act pertain to particular goods or circumstances, often delineated in subordinate instruments such as Therapeutic Goods Orders, which provide detailed requirements and standards. In the case of the consent granted to Abbvie Pty Ltd, the Act allows for certain deviations from standard labelling requirements, subject to specific conditions to ensure consumer safety and informed use, reflecting the Act’s flexibility to accommodate exceptional cases while maintaining its overarching regulatory objectives.

Key Provisions

Under sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act), the Department of Health, through a delegate of the Secretary, granted Abbvie Pty Ltd permission to import and supply VIEKIRA PAK-RBV, a medication used for treating certain medical conditions, on 26 November 2015. This consent allowed for the importation and supply of two specific formulations of VIEKIRA PAK-RBV that did not comply with certain labelling requirements as stipulated in paragraphs 3(2)(a), (l), and (j) of the Therapeutic Goods Order No. 69 – General requirements for labels for medicines. Specifically, the labels for these medications were in accordance with US standards rather than Australian standards. The consent was effective from 26 November 2015 until 31 July 2016 and was subject to specific conditions, including the use of particular 'daily wallet' labels and the distribution of a 'Dear Healthcare Provider / Pharmacist' letter to certain healthcare providers. The Therapeutic Goods Act 1989 imposes certain obligations on entities like Abbvie Pty Ltd that seek to import and supply therapeutic goods in Australia. In this case, Abbvie had to apply for consent under sections 14 and 14A of the Act and provide detailed information about the products and their compliance with Australian regulations. The consent granted by the Department of Health specified particular conditions that Abbvie had to adhere to, such as the use of specific labelling and the distribution of certain informational materials to healthcare providers. These obligations are designed to ensure that therapeutic goods available in Australia meet certain safety, quality, and efficacy standards. Failure to comply with the conditions set out in the consent, or more broadly, with the requirements of the Therapeutic Goods Act 1989, can lead to significant legal consequences. Under the Act, breaches can result in both civil and criminal penalties. Civil penalties can include fines and the requirement to cease certain activities. For instance, if Abbvie did not adhere to the specified labelling conditions, they could face fines and orders to stop the supply of the non-compliant products. Criminal penalties could include imprisonment, reflecting the seriousness with which the Australian government treats non-compliance with therapeutic goods regulations. The exact penalties depend on the nature and severity of the breach but can be severe, underscoring the importance of adhering to all conditions and obligations set out by the Act and any related orders.